Indian Regulators Halt Sun Pharma's Eye Drug Output at Assam Plant

what happened

Drug regulators in India have told Sun Pharmaceutical Industries to stop producing, selling and shipping eye-care drugs from its Assam site. The order, dated 20 August and reported by Moody's with a reference to Reuters, followed a joint inspection by central and state officials that found weaknesses in the company's quality controls.

The firm had already pulled about 11 eye-care brands in July as a precaution. Regulators want more information on other batches of ophthalmic suspensions, and it is unclear whether those are limited to the recalled brands. Output can resume only once authorities accept a compliance report, which is currently under review. The scale of any possible contamination and effects on patients have not been established.

On a 30 October earnings call, managing director Kirti Ganorkar described the production pause as voluntary and said remedial steps had been taken while the regulator was kept informed.

why it matters

Ophthalmology makes up roughly 3% of Sun Pharma's domestic sales according to its FY26 annual report, so the direct revenue hit looks contained. The bigger concern for investors is the pattern: the US FDA halted shipments from the Halol plant in Gujarat last year over contamination controls, and sterile manufacturing is a growth priority.

market impact

Sun Pharma shares: halted eye-drug output puts revenue and sterile-manufacturing plans at risk.

• ▼Sun Pharma shares pressure down — suspended eye-drug output weighs on near-term revenue

tags

instruments